Medtronic Leads $100 Million Strategic Investment in Pulnovo Medical

April 20, 2026
Pulnovo Medical has completed a $100 million strategic financing round led by Medtronic, with participation from existing and new investors. The two companies also signed a commercial agreement to explore future marketing opportunities for Pulnovo's pulmonary artery denervation system.

Pulnovo Medical has completed a 100 million dollar strategic financing round led by Medtronic, announced in a press release. Existing investors including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures also participated, along with new investors such as HSG and other global funds.

Pulnovo and Medtronic have signed a commercial agreement that outlines potential future marketing opportunities. The collaboration aims to leverage Medtronic's global commercial capabilities alongside Pulnovo's technology.

Pulnovo develops a patented pulmonary artery denervation (PADN) system designed to address key mechanisms in cardiopulmonary diseases. The company has conducted about 1,500 PADN procedures worldwide and secured regulatory approvals in seven countries. It is expanding commercialization in the European Union, the Middle East, and China.

In the United States, Pulnovo has received the FDA Breakthrough Device designation and launched two fully approved Investigational Device Exemption trials led by Dr. Gregg Stone of Mount Sinai.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Funding News AI Brief AI Brief (X)

More from: Life Sciences

04/20
Oracle Health Gains CMS Aligned Network Status, Expands Digital Check-In Solution
04/20
Nanostics Publishes Study Validating ClarityDX Prostate AI Models
04/20
Mitate Zepto Technica Joins JST Edge AI Semiconductor Program
04/20
Bracco Imaging and NYU Langone Health Form Multi-Year Research Alliance in Medical Imaging
04/20
Immunofoco Presents Preclinical Data for In Vivo CAR T Candidate IMV102 at AACR 2026

More from: Funding

04/20
Steele Solutions Acquires Maysteel Industries to Expand Data Center Capabilities
04/20
EnrollHere Receives Investment from Aquiline to Expand Medicare Advantage Platform
04/19
DeepSeek Plans $300 Million Fundraise at $10 Billion Valuation
04/17
Outcraft AI Raises €2M Pre-Seed to Advance Autonomous Sales Agents
04/17
Spektr Raises $20M Series A to Expand AI Compliance Automation

Subscribe to AI Funding Brief

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like